Tag Archives: Chronic Kidney Disease

← Older posts Newer posts →

Reata’s Kidney Drug Hits Goals of Key Study, Paves Way for FDA Filing

About half of all patients with the most severe form of Alport syndrome, a rare, genetic type of chronic kidney disease, will need dialysis or a transplant by age 25. On Monday, Reata Pharmaceuticals (NASDAQ: RETA) announced that its investigational drug for those with Alport syndrome, bardoxolone methyl (bard), met the main goal of a […]

Posted in National blog main, National top stories, Texas, Texas blog main, Texas top stories | Tagged , , , , , , , , , , , | Comments Off on Reata’s Kidney Drug Hits Goals of Key Study, Paves Way for FDA Filing

Alnylam Makes Case For 2nd RNAi Drug at Big Liver Disease Meeting

The “attacks,” as they’re known, are debilitating and even possibly fatal. A patient with the ultra-rare genetic disease acute hepatic porphyria (AHP) is struck with excruciating abdominal pain and rushes to a doctor’s office or hospital for some type of pain relief—even a surgery—to feel better. And then another attack could come, and another, driving […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Alnylam Makes Case For 2nd RNAi Drug at Big Liver Disease Meeting

Trevi Therapeutics Files for IPO to Fund Anti-Itching Drug R&D

Trevi Therapeutics is trying to turn an old opioid drug into a new therapy for tough-to-treat itching conditions, and it has filed for an initial public offering to finance clinical trials. In paperwork submitted to the SEC late Friday, Trevi set a preliminary $86 million target for its IPO. The New Haven, CT-based company has […]

Posted in National blog main, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Trevi Therapeutics Files for IPO to Fund Anti-Itching Drug R&D

IPO Wave Rolls On as Five Life Science Firms Haul In $651M

A week after seven biotechs went public, setting a new record for the Nasdaq, five more life sciences companies have joined the club. The latest crop continued the positive momentum for life sciences offerings, as the group either met or exceeded their projections and raised a total of $651 million. Neon Therapeutics (NASDAQ: NTGN) was […]

Posted in Boston blog main, Boston top stories, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Texas top stories, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , | Comments Off on IPO Wave Rolls On as Five Life Science Firms Haul In $651M

Akebia Merges With Keryx as Anemia Drug Race Nears Finish Line

The race to treat anemia with a pill, not an injectable biologic, just took a new turn. Akebia Therapeutics (NASDAQ: AKBA), which is battling with FibroGen (NASDAQ: FGEN) to bring an anemia pill to market, has just announced plans to merge with kidney drug disease developer Keryx Pharmaceuticals (NASDAQ: KERX) in an all-stock deal that […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main, New York top stories | Tagged , , , , , , , , , , | Comments Off on Akebia Merges With Keryx as Anemia Drug Race Nears Finish Line

Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease

Sanofi and Novo Nordisk this morning have put their venture arms to work. The two joined up with two venture firms to back a $49 million round for a fledgling startup, Inozyme Pharmaceuticals. The company aims to develop a therapy for an ultra-rare infant disorder—and possibly some more prevalent diseases too. The startup, based in […]

Posted in Boston, Boston blog main, Boston top stories, National blog main, New York blog main | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Inozyme Gets $49M From Sanofi, Novo to Tackle Rare Infant Disease

Proteon Therapeutics Plans Path Forward for Blood Vessel Drug

Three months ago, Proteon Therapeutics’ experimental blood vessel drug for people with failing kidneys flunked a Phase 3 clinical trial. The company now hopes that a larger study with a modified goal can produce different results. The Proteon (NASDAQ: PRTO) drug, vonapanitase, treats people whose chronic kidney disease has progressed to the point that they […]

Posted in Boston, Boston blog main, National blog main | Tagged , , , , , , | Comments Off on Proteon Therapeutics Plans Path Forward for Blood Vessel Drug

Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push

Akebia Therapeutics is in a high-stakes race with rival Fibrogen to treat anemia with a pill, not an injectable biologic. And it just got a bunch of cash to try to get to the clinical finish line. In a deal announced this morning, Japan’s Otsuka Pharmaceutical will commit $265 million to Cambridge, MA-based Akebia (NASDAQ: […]

Posted in Boston, Boston blog main, National blog main, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , | Comments Off on Akebia Gets $265M From Otsuka to Bankroll Anemia Drug Push

Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More

The 21st Century Cures Act is now law. New York wants to play in the biotech big leagues. The FDA under Trump will have license to approve drugs faster and could have a former top official back on board as commissioner. An eye drug failed, an Alzheimer’s drug got scrutinized, and a new antibiotic passed […]

Posted in Boston blog main, Boulder/Denver blog main, Boulder/Denver top stories, Detroit blog main, Detroit top stories, Indiana blog main, Indiana top stories, National, National blog main, National top stories, New York blog main, New York top stories, Raleigh-Durham blog main, Raleigh-Durham top stories, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories, Seattle blog main, Seattle top stories, Texas blog main, Wisconsin blog main, Wisconsin top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More

After Rival Stumbles, Relypsa Gets $1.5B Buyout Bid From Galenica

Relypsa got a big boost in May when a rival stumbled. Now it’s being rewarded with a buyout offer worth close to three times the price it went public at in 2013. Switzerland’s Galenica Group has agreed to buy Relypsa (NASDAQ: RLYP) for $32 a share in cash, or $1.53 billion overall, to grab rights […]

Posted in National blog main, National top stories, San Francisco, San Francisco blog main, San Francisco top stories, Texas blog main, Texas top stories | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on After Rival Stumbles, Relypsa Gets $1.5B Buyout Bid From Galenica← Older posts Newer posts →